A phase I/II trial of TAS-102 in combination with irinotecan in Japanese patients with advanced gastric cancer refractory to standard chemotherapies

Trial Profile

A phase I/II trial of TAS-102 in combination with irinotecan in Japanese patients with advanced gastric cancer refractory to standard chemotherapies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs Irinotecan (Primary) ; Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms T-SCAN study
  • Most Recent Events

    • 12 Jul 2018 Status changed from not yet recruiting to recruiting.
    • 01 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top